• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名IgA肾病患者合并抗磷脂综合征：一种罕见且具有挑战性的临床重叠情况。

Antiphospholipid Syndrome in a Patient With IgA Nephropathy: A Rare and Challenging Clinical Overlap.

作者信息

Al-Anbagi Usamah, Abusriwil Hatem M, Palol Azeez, Emsalem Mohamed, Abdelhamid Alaa, Nashwan Abdulqadir J

机构信息

Internal Medicine, Hazm Mebaireek General Hospital/Hamad Medical Corporation, Doha, QAT.

Medical Education, Hazm Mebaireek General Hospital/Hamad Medical Corporation, Doha, QAT.

出版信息

Cureus. 2025 Jul 7;17(7):e87462. doi: 10.7759/cureus.87462. eCollection 2025 Jul.

DOI:10.7759/cureus.87462
PMID:40772183
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12327936/
Abstract

Antiphospholipid syndrome (APS) is a rare autoimmune condition associated with a heightened risk of blood clots in arteries and veins due to the presence of specific antibodies. IgA nephropathy (IgAN), a kidney disorder involving immune complex deposition, is another immune-mediated disease. The coexistence of APS and IgAN is highly uncommon. We describe a young adult male with biopsy-confirmed kidney involvement who developed a significant clot in the lower limb. Despite appropriate treatment, the clot progressed, leading to complications in the lungs. Further investigation revealed laboratory findings consistent with APS. The patient underwent advanced interventions including clot removal and vascular procedures, followed by long-term treatment to prevent further clotting. This study emphasizes the clinical complexity when these two immune-mediated conditions overlap and underscores the importance of early detection and collaborative care in managing such rare and serious presentations.

摘要

抗磷脂综合征（APS）是一种罕见的自身免疫性疾病，由于存在特定抗体，导致动脉和静脉血栓形成风险增加。IgA肾病（IgAN）是一种涉及免疫复合物沉积的肾脏疾病，是另一种免疫介导的疾病。APS和IgAN同时存在极为罕见。我们描述了一名经活检证实有肾脏受累的年轻成年男性，其下肢出现了一个大的血栓。尽管进行了适当治疗，但血栓仍在进展，导致肺部出现并发症。进一步检查发现实验室检查结果与APS相符。患者接受了包括血栓清除和血管手术在内的高级干预措施，随后进行长期治疗以预防进一步血栓形成。本研究强调了这两种免疫介导疾病重叠时的临床复杂性，并强调了早期检测和协作护理在管理此类罕见且严重病症中的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a23/12327936/93d81c71d68f/cureus-0017-00000087462-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a23/12327936/d332cbb40bb9/cureus-0017-00000087462-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a23/12327936/6dbcd8d1b4bb/cureus-0017-00000087462-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a23/12327936/525e9f5193f6/cureus-0017-00000087462-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a23/12327936/93d81c71d68f/cureus-0017-00000087462-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a23/12327936/d332cbb40bb9/cureus-0017-00000087462-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a23/12327936/6dbcd8d1b4bb/cureus-0017-00000087462-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a23/12327936/525e9f5193f6/cureus-0017-00000087462-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a23/12327936/93d81c71d68f/cureus-0017-00000087462-i04.jpg

相似文献

1
Antiphospholipid Syndrome in a Patient With IgA Nephropathy: A Rare and Challenging Clinical Overlap.一名IgA肾病患者合并抗磷脂综合征：一种罕见且具有挑战性的临床重叠情况。
Cureus. 2025 Jul 7;17(7):e87462. doi: 10.7759/cureus.87462. eCollection 2025 Jul.
2
Home versus in-patient treatment for deep vein thrombosis.深静脉血栓形成的家庭治疗与住院治疗对比
Cochrane Database Syst Rev. 2018 Jan 9;1(1):CD003076. doi: 10.1002/14651858.CD003076.pub3.
3
Stopping anticoagulation for isolated or incidental pulmonary embolism: the STOPAPE RCT protocol.孤立性或偶发性肺栓塞抗凝治疗的停用：STOPAPE随机对照试验方案
Health Technol Assess. 2024 Jun;29(11):1-17. doi: 10.3310/HRCW7937.
4
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.抗血小板和抗凝药物用于抗磷脂综合征患者中风和其他血栓栓塞事件的二级预防。
Cochrane Database Syst Rev. 2017 Oct 2;10(10):CD012169. doi: 10.1002/14651858.CD012169.pub2.
5
Antiplatelet agents for the treatment of deep venous thrombosis.抗血小板药物治疗深静脉血栓形成。
Cochrane Database Syst Rev. 2022 Jul 25;7(7):CD012369. doi: 10.1002/14651858.CD012369.pub2.
6
Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.抗血小板和抗凝药物用于抗磷脂抗体个体血栓形成的一级预防。
Cochrane Database Syst Rev. 2018 Jul 13;7(7):CD012534. doi: 10.1002/14651858.CD012534.pub2.
7
Angioplasty or stenting for deep venous thrombosis.血管成形术或支架置入术治疗深静脉血栓形成。
Cochrane Database Syst Rev. 2025 Feb 19;2(2):CD011468. doi: 10.1002/14651858.CD011468.pub2.
8
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.口服直接凝血酶抑制剂或口服因子 Xa 抑制剂与传统抗凝剂治疗深静脉血栓形成的比较。
Cochrane Database Syst Rev. 2023 Apr 14;4(4):CD010956. doi: 10.1002/14651858.CD010956.pub3.
9
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.用于治疗深静脉血栓形成的口服直接凝血酶抑制剂或口服Xa因子抑制剂。
Cochrane Database Syst Rev. 2015 Jun 30(6):CD010956. doi: 10.1002/14651858.CD010956.pub2.
10
Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.对无诱因静脉血栓栓塞症（VTE）患者进行癌症检测对癌症及VTE相关死亡率和发病率的影响。
Cochrane Database Syst Rev. 2017 Aug 23;8(8):CD010837. doi: 10.1002/14651858.CD010837.pub3.

本文引用的文献

1
An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.抗磷脂综合征诊断中抗磷脂抗体实验室检测与解读的最新进展：国际血栓与止血学会（ISTH）-抗磷脂抗体标准化委员会狼疮抗凝物/抗磷脂抗体小组委员会的指南
J Thromb Haemost. 2025 Feb;23(2):731-744. doi: 10.1016/j.jtha.2024.10.022. Epub 2024 Nov 5.
2
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.2023年美国风湿病学会/欧洲抗风湿病联盟抗磷脂综合征分类标准。
Arthritis Rheumatol. 2023 Oct;75(10):1687-1702. doi: 10.1002/art.42624. Epub 2023 Aug 28.
3
Long-Term Outcomes in IgA Nephropathy.
IgA 肾病的长期预后。
Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13.
4
- and -Glycosylation of Serum Immunoglobulin A is Associated with IgA Nephropathy and Glomerular Function.- 糖基化的血清免疫球蛋白 A 与 IgA 肾病和肾小球功能有关。
J Am Soc Nephrol. 2021 Oct;32(10):2455-2465. doi: 10.1681/ASN.2020081208. Epub 2021 Jun 14.
5
Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.抗磷脂综合征肾病：从发病机制到治疗
Front Immunol. 2018 May 31;9:1181. doi: 10.3389/fimmu.2018.01181. eCollection 2018.
6
Diagnosis and Management of the Antiphospholipid Syndrome.抗磷脂综合征的诊断与管理
N Engl J Med. 2018 May 24;378(21):2010-2021. doi: 10.1056/NEJMra1705454.
7
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.抗磷脂抗体在系统性红斑狼疮中的临床意义。
Eur J Rheumatol. 2016 Jun;3(2):75-84. doi: 10.5152/eurjrheum.2015.0085. Epub 2015 Dec 29.
8
Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.牛津IgA肾病分类在不同临床表现和治疗的队列中的验证。
Kidney Int. 2014 Oct;86(4):828-36. doi: 10.1038/ki.2014.63. Epub 2014 Apr 2.
9
Rare association of cutaneous vasculitis, IgA nephropathy and antiphospholipid antibody syndrome with tuberculous lymphadenitis.皮肤血管炎、IgA肾病、抗磷脂抗体综合征与结核性淋巴结炎的罕见关联。
Clinics (Sao Paulo). 2013 Jul;68(7):1072. doi: 10.6061/clinics/2013(07)29.
10
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.牛津 IgA 肾病临床病理分类对儿童和成人均有效。
Kidney Int. 2010 May;77(10):921-7. doi: 10.1038/ki.2010.43. Epub 2010 Mar 3.